Category: Front Page

Crescendo Biologics announces clinical biodistribution data of Humabody® bispecific CB307 at ESMO 2024 View PDF Read more

Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a… Read more

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager… Read more

Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307 View PDF Read more

Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC View… Read more

Crescendo Biologics wins significant European Patent Office ruling related to the engineering of immunoglobulin technology View PDF Read more

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours View PDF Read more

Crescendo Biologics is category winner for Biopharma and Vaccinesin 2023 UK DIT Life Sciences Innovator Showcase View PDF Read more

Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio View PDF Read more

BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies View PDF Read more

Crescendo Biologics announces publication of data for CB213, a PD-1xLAG-3 multi-specific Humabody®, in the British Journal of Cancer View PDF Read more

Crescendo Biologics wins “Best Established Biotech Company” at the 2021 OBN Awards View PDF Read more

Crescendo Biologics announces that Zai Lab has achieved proof-of-concept for ZL-1102 (Humabody®, CB001) in a Phase 1b clinical trial in… Read more

Crescendo Biologics announces prestigious new collaboration with The Institute of Cancer Research, London View PDF Read more

Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours View PDF Read more

Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer View PDF Read more

Crescendo to participate in upcoming investor conferences View PDF Read more

Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology View PDF Read more

New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours View… Read more